Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
2
Bullish
8
Bearish
36
Neutral
2
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
4
Neutral
2
Bullish
8
Bearish
4
Neutral
2
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Upcoming Result Date: Nov 03, 2026
Denis Chem Lab Ltd (DENISCHEM) is currently trading at 60.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Denis Chem Lab Limited manufactures sterile parenteral transfusion solutions (IV fluids) filled in glass and PP plastic bottles using automated Blow‑Fill‑Seal (BFS) technology, operating GMP/WHO‑compliant facilities with historical installed BFS capacity of 15 million units per annum and later Eurohead line additions targeting premium segments. In Q1 FY2026 (quarter ended 30 June 2026) Denis Chem Lab reported total income of Rs. 4,444.67 lakh and profit before tax of Rs. 264.37 lakh, translating to a PAT of Rs. 204.52 lakh and basic EPS of Rs. 1.47, reflecting sequential recovery in profitability driven by lower employee and other operating expenses. The company reports zero financial indebtedness on its disclosures, signalling a debt‑free balance sheet at the reporting date which supports financial flexibility for Denis Chem Lab Limited but may limit leveraged growth options without new capital infusion. Commercial strategy highlights include expansion of the premium 'Euro head' product range, expanded domestic market penetration via larger sales force and distributor reach, and deliberate use of third‑party manufacturing to deepen the injectable product basket and optimise distribution assets. Regulatory and accounting items are notable: the company is monitoring implementation of India’s new labour codes with an accounting impact previously recorded on gratuity and privilege leaves; statutory auditors issued an unmodified review opinion on the quarter’s unaudited results for Denis Chem Lab Limited.
Over the past 52 weeks, Denis Chem Lab Ltd has traded between a low of ₹56.10 and a high of ₹94.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Denis Chem Lab Ltd has a market capitalization of approximately 83.26. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Denis Chem Lab Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 10.43 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 83.26 Cr, Denis Chem Lab Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Denis Chem Lab Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Denis Chem Lab Ltd is 10.43. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discovery themes featuring this stock
Denis Chem Lab Limited manufactures sterile parenteral transfusion solutions (IV fluids) filled in glass and PP plastic bottles using automated Blow‑Fill‑Seal (BFS) technology, operating GMP/WHO‑compliant facilities with historical installed BFS capacity of 15 million units per annum and later Eurohead line additions targeting premium segments.
In Q1 FY2026 (quarter ended 30 June 2026) Denis Chem Lab reported total income of Rs. 4,444.67 lakh and profit before tax of Rs. 264.37 lakh, translating to a PAT of Rs. 204.52 lakh and basic EPS of Rs. 1.47, reflecting sequential recovery in profitability driven by lower employee and other operating expenses.
The company reports zero financial indebtedness on its disclosures, signalling a debt‑free balance sheet at the reporting date which supports financial flexibility for Denis Chem Lab Limited but may limit leveraged growth options without new capital infusion.
Commercial strategy highlights include expansion of the premium 'Euro head' product range, expanded domestic market penetration via larger sales force and distributor reach, and deliberate use of third‑party manufacturing to deepen the injectable product basket and optimise distribution assets.
Regulatory and accounting items are notable: the company is monitoring implementation of India’s new labour codes with an accounting impact previously recorded on gratuity and privilege leaves; statutory auditors issued an unmodified review opinion on the quarter’s unaudited results for Denis Chem Lab Limited.
Pharmaceuticals & Biotechnology
Pharmaceuticals
83 Cr
Low Risk
10.4
34.8
11.5
0.9
94.60
56.10
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
44.99 | 90 Cr | 8.02 | 1.12 | 1.11 | 13.48 | 18.36 | 12.76 | ||
68.06 | 90 Cr | 43.74 | 1.92 | 0.00 | 2.17 | 5.12 | 2.74 | ||
731.05 | 88 Cr | 21.04 | 1.51 | 0.48 | 8.32 | 10.75 | 5.27 | ||
277.50 | 86 Cr | -38.80 | 1.26 | 0.00 | -4.86 | -2.57 | -1.78 | ||
60.00 | 83 Cr | 10.43 | 0.91 | 4.17 | 9.18 | 13.14 | 6.39 | ||
50.95 | 78 Cr | 40.26 | 2.74 | 0.00 | 6.80 | 10.18 | 5.52 | ||
30.36 | 76 Cr | -3.26 | 8.89 | 0.00 | -117.84 | -25.84 | -37.84 | ||
| Median: 7 Co. | — | 60.00 | 86 Cr | 10.43 | 1.51 | 0.00 | 6.80 | 10.18 | 5.27 |
